What is Cibinqo and what is it used for?

Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase inhibitors and works by reducing the activity of an enzyme in the body called ‘Janus kinase’, which is involved in inflammation.

Cibinqo is used to treat adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis, also known as atopic eczema, who are candidates for systemic therapy.

Cibinqo is a pink tablet and comes in three different strengths: 200mg, 100mg, 50mg.

The medicine can only be obtained with a prescription.


Reference Information
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cibinqo visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.